Acadian Asset Management LLC purchased a new position in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 173,539 shares of the company’s stock, valued at approximately $250,000. Acadian Asset Management LLC owned approximately 0.33% of Spero Therapeutics as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Royce & Associates LP acquired a new position in shares of Spero Therapeutics during the 2nd quarter worth $33,000. Mackenzie Financial Corp acquired a new position in shares of Spero Therapeutics during the 2nd quarter worth $25,000. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the 2nd quarter worth $32,000. Anson Funds Management LP raised its holdings in shares of Spero Therapeutics by 10.8% during the 1st quarter. Anson Funds Management LP now owns 3,344,862 shares of the company’s stock worth $4,850,000 after buying an additional 325,254 shares in the last quarter. Finally, Engineers Gate Manager LP acquired a new position in shares of Spero Therapeutics during the 1st quarter worth $95,000. Institutional investors and hedge funds own 27.25% of the company’s stock.
Insider Buying and Selling
In related news, insider Kamal Hamed sold 39,496 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $1.27, for a total transaction of $50,159.92. Following the sale, the insider now owns 576,461 shares in the company, valued at approximately $732,105.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 54,553 shares of company stock worth $69,298 in the last 90 days. Insiders own 4.21% of the company’s stock.
Analyst Ratings Changes
Spero Therapeutics Stock Up 2.6 %
Shares of SPRO stock opened at $1.19 on Friday. The firm has a market capitalization of $63.07 million, a P/E ratio of 119.00 and a beta of 0.87. Spero Therapeutics, Inc. has a twelve month low of $0.99 and a twelve month high of $2.04. The stock’s fifty day simple moving average is $1.16 and its 200 day simple moving average is $1.42.
Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last issued its quarterly earnings data on Monday, November 13th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.17. The business had revenue of $25.47 million for the quarter, compared to analyst estimates of $2.40 million. Spero Therapeutics had a positive return on equity of 4.14% and a negative net margin of 2.08%. As a group, equities research analysts expect that Spero Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.
Spero Therapeutics Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
- Five stocks we like better than Spero Therapeutics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 11/13 – 11/17
- Pros And Cons Of Monthly Dividend Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.